Switch theme
Sign up to access all valuation multiples
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
2017
63
LTM Revenue n/a
LTM EBITDA -$303M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akero Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$303M.
In the most recent fiscal year, Akero Therapeutics achieved revenue of n/a and an EBITDA of -$247M.
Akero Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akero Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$149M | -$247M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$112M | -$152M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Akero Therapeutics's stock price is $38.
Akero Therapeutics has current market cap of $3.0B, and EV of $2.3B.
See Akero Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $3.0B | XXX | XXX | XXX | XXX | $-3.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Akero Therapeutics has market cap of $3.0B and EV of $2.3B.
Akero Therapeutics's trades at n/a LTM EV/Revenue multiple, and -7.5x LTM EBITDA.
Analysts estimate Akero Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akero Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.2x | XXX | XXX | XXX |
| P/E | -11.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -9.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkero Therapeutics's NTM/LTM revenue growth is Infinity%
Akero Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.5M for the same period.
Over next 12 months, Akero Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akero Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akero Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 66% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $4.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akero Therapeutics acquired XXX companies to date.
Last acquisition by Akero Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Akero Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Akero Therapeutics founded? | Akero Therapeutics was founded in 2017. |
| Where is Akero Therapeutics headquartered? | Akero Therapeutics is headquartered in United States of America. |
| How many employees does Akero Therapeutics have? | As of today, Akero Therapeutics has 63 employees. |
| Who is the CEO of Akero Therapeutics? | Akero Therapeutics's CEO is Dr. Andrew Cheng, M.D.,PhD. |
| Is Akero Therapeutics publicy listed? | Yes, Akero Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Akero Therapeutics? | Akero Therapeutics trades under AKRO ticker. |
| When did Akero Therapeutics go public? | Akero Therapeutics went public in 2019. |
| Who are competitors of Akero Therapeutics? | Similar companies to Akero Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Akero Therapeutics? | Akero Therapeutics's current market cap is $3.0B |
| What is the current EBITDA of Akero Therapeutics? | Akero Therapeutics's last 12-month EBITDA is -$303M. |
| What is the current EV/EBITDA multiple of Akero Therapeutics? | Current EBITDA multiple of Akero Therapeutics is -7.5x. |
| Is Akero Therapeutics profitable? | Yes, Akero Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
